Alzheimer’s changed the couple’s routine, but not their fight to keep going. Together, David and Pamela are awareness advocates for the Alzheimer’s Association. They’ve met with representatives on ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...
Researchers have developed a simple model system that can be used to break down fibrils -- the cause of numerous disorders including Alzheimer's and Parkinson's disease -- into their constituent ...
The Associated Press noted that one of FDA’s requirements calls for drug companies to show on-screen text about side effects while the audio information plays. RELATED: Eli Lilly's Alzheimer's drug ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback